Zentalis selected the 400 mg dose of its drug to treat ovarian cancer after it showed a higher response rate than the 300 mg dose. ・The company expects to complete enrollment and report topline ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...

On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026. The firm shed light on the biopharma segment, which is entering 2026 with renewed momentum and a ...

Jefferies has identified its top picks in the small and mid-cap (SMID) biotechnology sector, highlighting three companies poised for significant growth driven by ...

Brokers are upbeat and see upside of up to 125%! The post Is this battered ASX biotech stock ready to rocket higher? appeared ...

IBT's Ailsa Craig and Marek Poszepczynski give their key stock picks as companies move on from the science to commercial ...